Trial Profile
A study evaluating role of secondary prophylaxis with valganciclovir in the prevention of recurrent cytomegalovirus disease in solid organ transplant recipients.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 24 Oct 2017
Price :
$35
*
At a glance
- Drugs Valganciclovir (Primary)
- Indications Cytomegalovirus infections
- Focus Therapeutic Use
- 24 Oct 2017 New trial record
- 08 Oct 2017 Results presented at the IDWeek 2017